Search
Showing results for "clinical trials"
Head, Strong Beginnings Research, Co-head Foundations of Lung Disease
The WA Kids Cancer Centre has secured $1.1 million in funding from the Medical Research Future Fund’s (MRFF) Paediatric Brain Cancer Research Stream 2 to develop more effective and less toxic treatments for rare brain cancers in infants.
Peter Britta Richmond Regli-von Ungern-Sternberg AM FAHMS MBBS MRCP(UK) FRACP MD, PhD, DEAA, FANZA Head, Vaccine Trials Group Chair of Paediatric
In this review, we comprehensively evaluate the rationale for oxytocin as a therapeutic, evaluating evidence from various various sources.
Our objective was to examine influenza vaccine safety in Australian children aged under 10 years in 2013.
Encephalitis is most often caused by a variety of infectious agents identified through diagnostic tests utilizing cerebrospinal fluid. We investigated the clinical characteristics and potential aetiological agents of unexplained encephalitis through metagenomic sequencing of residual clinical samples from multiple tissue types and independent clinical review.
Pat Peter Tom Holt Richmond Snelling PhD, DSc, FRCPath, FRCPI, FAA MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid PhD FRACP Emeritus Honorary Researcher
Determine the frequency of detection of specific viral pathogens in children with febrile seizures
Christopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and
Introduction Grades 2 and 3 gliomas (G2/3 gliomas), when combined, are the second largest group of malignant brain tumours in adults. The outcomes for G2/3 gliomas at progression approach the dismal outcomes for glioblastoma (GBM), yet there is a paucity of trials for Australian patients with relapsed G2/3 gliomas compared with patients with GBM.